Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 6.72M |
Gross Profit | 0.00 | -1.68M | -1.49M | -1.28M | 6.72M |
EBITDA | -39.90M | -43.89M | -56.67M | -48.52M | -30.84M |
Net Income | -39.40M | -45.80M | -58.69M | -49.88M | -32.12M |
Balance Sheet | |||||
Total Assets | 43.20M | 44.05M | 51.01M | 56.80M | 32.16M |
Cash, Cash Equivalents and Short-Term Investments | 27.40M | 36.22M | 41.80M | 53.13M | 26.21M |
Total Debt | 0.00 | 4.54M | 6.04M | 986.00K | 2.00M |
Total Liabilities | 11.13M | 13.38M | 16.49M | 10.13M | 10.04M |
Stockholders Equity | 32.07M | 30.67M | 34.51M | 46.67M | 22.11M |
Cash Flow | |||||
Free Cash Flow | -40.40M | -45.74M | -55.09M | -46.17M | -32.22M |
Operating Cash Flow | -40.40M | -45.74M | -54.85M | -46.17M | -32.22M |
Investing Cash Flow | 0.00 | 0.00 | -245.00K | 0.00 | 0.00 |
Financing Cash Flow | 31.60M | 40.16M | 43.76M | 73.09M | -1.25M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | kr70.83M | ― | -126.57% | ― | 36.91% | 49.66% | |
50 Neutral | kr5.39B | 12.66 | -80.61% | 5.12% | 37.36% | 27.71% | |
46 Neutral | kr97.19M | ― | -151.10% | ― | 230.57% | 46.64% | |
39 Underperform | kr223.96M | ― | ― | -8.47% | ― | ||
34 Underperform | €105.91M | ― | -56.71% | ― | ― | 35.61% | |
32 Underperform | kr236.19M | ― | -186.40% | ― | ― | 24.47% |
Active Biotech AB has announced its Annual General Meeting (AGM) scheduled for May 28, 2025, where shareholders will discuss key resolutions including the re-election of board members and auditors, and the decision to carry forward the company’s accumulated loss without distributing dividends. This meeting is significant for stakeholders as it addresses the company’s governance and financial strategy moving forward.
Active Biotech AB has announced its Annual General Meeting (AGM) scheduled for May 28, 2025, in Lund, Sweden. The meeting will address standard AGM procedures including the election of board members and auditors, with the re-election of current board members and auditors proposed. The company has decided not to distribute dividends, opting instead to carry forward accumulated losses.
Active Biotech AB has announced its Annual General Meeting (AGM) scheduled for May 28, 2025, in Lund, Sweden. Key agenda items include the re-election of board members and the decision to carry forward the company’s accumulated loss without paying dividends. The AGM will also address the re-election of Öhrlings PricewaterhouseCoopers AB as the company’s auditor, with no changes to the board’s remuneration.
Active Biotech AB has announced its Annual General Meeting (AGM) scheduled for May 28, 2025, in Lund, Sweden. The meeting will address various resolutions, including the re-election of board members and auditors, and the proposal to carry forward the company’s accumulated loss without paying dividends. This AGM is significant for stakeholders as it outlines the company’s governance and financial strategies moving forward.
Active Biotech AB has announced its upcoming Annual General Meeting scheduled for May 28, 2025, where shareholders will discuss various resolutions including the re-election of board members and the proposal to carry forward the company’s accumulated loss without paying dividends. The meeting will also address the re-election of Öhrlings PricewaterhouseCoopers AB as the auditor, indicating a stable continuity in the company’s governance and financial oversight.
Active Biotech AB has announced its upcoming Annual General Meeting (AGM) scheduled for May 28, 2025. Key agenda items include the re-election of board members and auditors, with no dividend to be paid as the company’s accumulated loss will be carried forward. The meeting will also address board remuneration and share issue authorization, impacting the company’s governance and financial strategy moving forward.
Active Biotech AB has announced its Annual General Meeting (AGM) scheduled for May 28, 2025, where shareholders will discuss key resolutions including the re-election of board members and auditors, and the decision to carry forward the company’s accumulated loss without paying dividends. The AGM will also address board remuneration and share issue authorization, reflecting the company’s strategic focus on maintaining financial stability and governance continuity.
Active Biotech AB has announced its Annual General Meeting (AGM) scheduled for May 28, 2025, in Lund, Sweden. Shareholders are invited to participate, with key agenda items including the election of board members and auditors, and resolutions on the company’s financial statements. The board proposes no dividend distribution, opting to carry forward the accumulated loss, and recommends re-election of current board members and auditors.